142374-22-9

Upstream product

• 28356-58-3 pyridine-4-acetic acid 
• 51052-78-9 4-piperidinylacetic acid 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 142374-19-4 tert-butyl 4-(formylmethyl)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 142-61-0 Hexanoyl chloride 
• 113850-77-4 (S)-methyl 2-amino-3-(4-iodophenyl)propanoate 
• 142374-18-3 (S)-2-Hexanoylamino-3-(4-iodo-phenyl)-propionic acid methyl ester 

Downstream Products

• 142374-23-0 4-{5-[4-((S)-2-Hexanoylamino-2-methoxycarbonyl-ethyl)-phenyl]-pentyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 142374-24-1 4-{5-[4-((S)-2-Carboxy-2-hexanoylamino-ethyl)-phenyl]-pentyl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation.Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation.Compound 23m (L-700, 462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of >24000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors.Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions 0.1-10 μg/kg/min of 23m in anesthetized dogs, with 10 μg/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol.Platelet aggregatability returned rapidly after the termination of the 23m infusions.These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.